重组人脑利钠肽对急性心肌梗死经皮冠状动脉介入治疗术后并发急性左心衰竭患者的临床观察Clinical observation of recombinant human brain natriuretic peptide in patients with acute left heart failure complicated with acute myocardial infarction after percutaneous coronary intervention
母雪飞,赵昕,任丽丽,王丽,顾崇怀,王效增,韩雅玲
摘要(Abstract):
目的观察重组人脑利钠肽(recombinant human brain natriuretic peptide,rh BNP)对急性心肌梗死(acute myocardial infarction,AMI)入院后24 h行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后并发急性左心衰竭(acute left heart failure,AHF)的疗效。方法回顾分析2012年6月至2014年1月在沈阳军区总医院住院治疗的AMI行PCI术后并发AHF患者229例,根据患者的经济条件及知情同意后分为常规药物治疗心力衰竭组122例(对照组)及常规药物治疗心力衰竭基础上应用rh BNP组107例(观察组)。观察两组患者治疗前后心力衰竭症状的改善情况,住院和随访30 d及12个月的死亡率。结果两组患者治疗72 h后的心率、收缩压、氨基末端B型脑钠肽前体(NT-pro BNP)均较治疗前显著下降(均P<0.05),观察组心率、NT-pro BNP较对照组下降幅度更显著(P<0.05),观察组Killip心功能Ⅱ~Ⅲ级改善情况(所占比率的降低幅度)显著优于对照组[78例(72.9%)比67例(54.9%),P=0.005]。观察组住院期间[5例(4.7%)比8例(6.6%),P=0.539]、随访30 d[7例(6.5%)比14例(11.5%),P=0.197]、12个月[7例(6.5%)比17例(13.9%),P=0.068]的死亡率均低于对照组。多因素logistic回归分析显示,NT-pro BNP水平(OR 0.999,95%CI 0.999~1.000,P=0.000)及应用rh BNP治疗(OR 0.084,95%CI 0.015~0.483,P=0.006)是AMI患者PCI术后并发AHF远期(12个月)死亡率的独立影响因素。结论常规治疗基础上加用rh BNP治疗AMI患者PCI术后并发AHF与常规治疗比较,可降低12个月的死亡率,改善患者预后,值得临床推广应用。
关键词(KeyWords): 急性心肌梗死;经皮冠状动脉介入治疗;急性左心衰竭;重组人脑利钠肽
基金项目(Foundation): 辽宁省自然科学基金(201102241)
作者(Author): 母雪飞,赵昕,任丽丽,王丽,顾崇怀,王效增,韩雅玲
参考文献(References):
- [1]重组人脑利钠肽多中心研究协作组.重组人脑利钠肽治疗心力衰竭安全性和疗效的开放性随机对照多中心临床研究.中华心血管病杂志,2011,39(4):305-308.
- [2]White HD,Thygesen K,Alpert JS,et al.clinical implications of the third universal definition of myocardial infarction.Heart,2014,100(5):424-432.
- [3]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南.中华心血管病杂志,2010,38(3),195-208.
- [4]Balion CM,Santaguida P,Mc Kelvie R,et al.Physiological,pathological,pharmacological,biochemical and hematological factors affecting BNP and NT-pro BNP.Clin Biochem,2008,41(4-5):231-239.
- [5]Pandey KN.Guanylyl cyclase/atrial natriuretic peptide receptorA:role in the pathophysiology of cardiovascular regulation.Can J Physiol Pharmacol,2011,89(8):557-573.
- [6]Weintraub NL,Colins SP,Pang PS,et a1.Acute heart failure syndromes:emergency department presentation,treatment,and disposition:current approaches and future aims:a scientific statement from the American Heart Association.Circulation,2010,122(19):1975-1996.
- [7]谢洪智,朱文玲.重组人脑利钠肽和硝酸甘油治疗急性失代偿性心力衰竭疗效和安全性的随机、开放、平行对照的多中心临床研究.中华心血管病杂志,2006,34(3):225.
- [8]王日军,李慧芳,张月安.重组人脑利钠肽治疗老年慢性心衰患者急性加重期的临床疗效观察.中国老年学杂志,2010,30(5):1176-1178.
- [9]Hamada Y,Tanaka N,Murata K,et a.Significance of predischarge BNP on one-year outcome in decompensated heart failure-comparative study with echo-Doppler indexes.J Card Fail.2005,Feb,11(1):43-49.
- [10]张晶,傅向华,樊欣娜,等.急性前壁心肌梗死伴心力衰竭患者急诊经皮冠状动脉介入治疗围手术期应用重组人B型钠尿肽的心肾保护效应.中国危重病急救医学,2010,22(11):669-673.
- [11]Publication Committee for the VMAC Investigators.Intravenous nesiritide VS nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlledtrial.JAMA,2002,287(12):1531-1540.